ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers API solutions, such as small molecules, highly potent, carbapenems, glycans, peptides, oligonucleotides, and therapeutic enzymes; GMP, non-GMP, asymchem lab facilities and capabilities, commercial manufacturing, clinical man… Read more
ASYMCHEM LAB.(TIAN.)H YC1 (7K90) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ASYMCHEM LAB.(TIAN.)H YC1 - Net Assets Trend (None–None)
This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ASYMCHEM LAB.(TIAN.)H YC1 (None–None)
The table below shows the annual net assets of ASYMCHEM LAB.(TIAN.)H YC1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ASYMCHEM LAB.(TIAN.)H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Market Cap
The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hengan International Group Company Limited
F:HGNC
|
$1.98 Billion |
|
Bachem Holding AG
PINK:BCHMF
|
$1.98 Billion |
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
$1.98 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
$1.98 Billion |
|
Harley-Davidson Inc
NYSE:HOG
|
$1.98 Billion |
|
Indian Railway Finance Corporation Limited
NSE:IRFC
|
$1.98 Billion |
|
Gold Road Resources Limited
PINK:ELKMF
|
$1.98 Billion |
|
Siriuspoint Ltd
NYSE:SPNT
|
$1.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ASYMCHEM LAB.(TIAN.)H YC1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ASYMCHEM LAB.(TIAN.)H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ASYMCHEM LAB.(TIAN.)H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ASYMCHEM LAB.(TIAN.)H YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ASYMCHEM LAB.(TIAN.)H YC1 (7K90) | €- | N/A | N/A | $1.98 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |